Chrysea presents additional study results at Gordon Research Conference (GRC)
At BFLS, significant associations reported in a large representative cohort of 8965 Americans between higher spermidine intake levels and lower cardiovascular risk […]
Benchmarking ML in ADMET predictions: the practical impact of feature representations in ligand-based models
Abstract This study, focusing on predicting Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) properties, addresses the key challenges of ML models trained […]
Greg at Founders forum
Our co-founder, Dr. Greg Bailey, shared key insights on longevity science and the latest exciting developments at Juvenescence® during the Founders Forum […]
Team at Middle East Investors Summit
We were glad to participate in the recent Middle East Investors Summit – a dynamic gathering of global investors, family offices, and […]
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 […]
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 […]
Incredible week at Abu Dhabi Global Health Week
Packed with bold ideas, global collaboration, and a shared vision for a future built on preventative, personalised healthcare.
M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence
M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.
Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m
Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company.
Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.
Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.